InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases a new version of LikelihoodProfiler.jl. LikelihoodProfiler represents a unified Julia package that can be used for practical identifiability analysis for complex computationally demanding QSP models.
Initially, LikelihoodProfiler.jl included a method (CICO) for estimating confidence intervals (CI) and assessing the practical identifiability of model parameters using the profile likelihood approach. Now LikelihoodProfiler package provides various state-of-the-art methods for profile likelihood analysis, including optimization-based and integration-based profiles, CI endpoints search, and more. These methods are now unified under a new interface, making it easier for users to switch between them. The results of LikelihoodProfiler.jl analysis can be used to further reduce the complexity and eliminate model’s uncertainty by implementing identifiable parametrizations and model reduction techniques.
Ivan Borisov, Senior Software Developer, comments on the new version of LikelihoodProfiler.jl, “This release marks the first version of the revamped package. We plan to introduce additional methods, improve interfaces, enhance documentation, and more to make the package more valuable to the community.”
LikelihoodProfiler package is open-source and freely available on GitHub: https://github.com/insysbio/LikelihoodProfiler.jl
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | February 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
1.
19 Feb 2020 12:54
InSysBio to participate in ASCPT 2020
InSysBio announced its participation in 121st Annual meeting of American Society for Clinical Pharmacology and Therapeutics (ASCPT 2020) which is to be held on March 18-21, 2020 at Marriott Marquis Houston, TX. InSysBio welcomes visitors at the booth # 102. Oleg Demin, CEO of InSysBio, Tatiana Karelina, lead modeler in Alzheimer's Disease and Veronika Musatova, Head of IRT development team, will present the new version of IRT (Immune Response Template) and Cytocon DB (Cell and cYTOkine CONcentrations).
|
20
|
21
1.
21 Feb 2020 17:02
InSysBio presents an enhanced version of its Immune Response Template Database
IRT Version 3.0.0 acquires a wide variety of updates and new options
(Moscow – 21.02.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) platform development and provision, moves forward to the future.
|
22
|
23
|
|
24
|
25
|
26
|
27
|
28
|
29
| |
Thank you for your message! We will get back to you shortly.
